Phaseline

Targets › COL18A1

COL18A1 (Collagen alpha-1(XVIII) chain [Cleaved into: Endostatin; Non-collagenous domain 1): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 2; Oncology; next expected readout Feb 2027.

Probably plays a major role in determining the retinal structure as well as in the closure of the neural tube..; FUNCTION: [Non-collagenous domain 1]: May regulate extracellular matrix-dependent motility and morphogenesis of endothelial and non-endothelial cells; the function requires homotrimerization and implicates MAPK signaling..; FUNCTION: [Endostatin]: Potently inhibits endothelial cell proliferation and…. (UniProt, P39060)

Open in Phaseline: the race on COL18A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chongqing University Cancer HospitalRecombinant human endostatin
Endostatin - angiogenesis inhibitor derived from collagen XVIII
COL18A1Phase 2Nasopharyngeal CarcinomaFeb 2027
Hua ZhangRecombinant Human Endostatin Injection (Endostar)
Endogenous angiogenesis inhibitor; anti-angiogenic agent
COL18A1Phase 2Unresectable Non-small Cell Lung CancerSep 2027

Conditions

Unresectable Non-small Cell Lung Cancer (1) Nasopharyngeal Carcinoma (1)

Modalities

antibody (2)

Companies

Hua Zhang (1) Chongqing University Cancer Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.